Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Innovent BiologicsHKSE:01801 -5.57%84 Interest Coverage is 46.21 as of Dec. 2025, which is 201% above its 10-year median of 15.36. GuruFocus rates HKSE:01801 with a GF Score™ of 84/100 and a GF Value™ of HK$100.93 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 376 Biotechnology companies, Innovent Biologics ranks worse than 63.83% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Innovent Biologics's
Operating Income
for the
six
months ended in Dec. 2025 was HK$936 Mil. Innovent Biologics's Interest Expense for the
six
months ended in Dec. 2025 was HK$-20 Mil.
Innovent Biologics's interest coverage for the quarter that ended in Dec. 2025 was 46.21.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Innovent Biologics's Interest Coverage or its related term are showing as below:
HKSE:01801'
s Interest Coverage Range Over the Past 10 Years
Min: 3.82 Med: 15.36 Max: 26.94
Current: 26.94
HKSE:01801's Interest Coverage is ranked worse than 63.83% of 376
companies
in the Biotechnology industry
Industry Median: 104.025
vs HKSE:01801: 26.94
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Innovent Biologics Interest Coverage Related Terms
Innovent Biologics Interest Coverage Historical Data
* Premium members only.
The historical data trend for Innovent Biologics's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
HKSE:01801 vs VRTX, REGN, ALNY: Interest Coverage Comparison
For the Biotechnology subindustry, Innovent Biologics's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innovent Biologics Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Innovent Biologics's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Innovent Biologics's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innovent Biologics (HKSE:01801) has a Interest Coverage of 46.21 as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Innovent Biologics and its competitors. This is 201% above median its historical median of 15.36. Over the past decade, Innovent Biologics' Interest Coverage has ranged from 3.82 to 26.94. According to the industry distribution chart, Innovent Biologics ranks #240 out of 376 companies in the Biotechnology industry, placing it in the top 63.8%.
Is Innovent Biologics' Interest Coverage too high?
Innovent Biologics' current Interest Coverage of 46.21 is 201% above median its 10-year median of 15.36. Over the past 10 years, this metric has ranged from a low of 3.82 to a high of 26.94. The Biotechnology industry median Interest Coverage is 104.03. Innovent Biologics' value of 46.21 is 55.6% below this industry median. Based on the distribution chart, Innovent Biologics ranks #240 out of 376 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Innovent Biologics has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Innovent Biologics' Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Innovent Biologics ranks #240 out of 376 companies for Interest Coverage. This places Innovent Biologics in the lower half of its industry. The industry median Interest Coverage is 104.03. Innovent Biologics' value of 46.21 is 55.6% below this benchmark. Historically, Innovent Biologics' own Interest Coverage has ranged from 3.82 to 26.94 over the past decade. While the company's 10-year median is 15.36 vs. the industry median of 104.03, Innovent Biologics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 104.03, based on 376 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Innovent Biologics's current Interest Coverage of 46.21 is 55.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Innovent Biologics and its competitors. For the Biotechnology industry, the median Interest Coverage is 104.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Innovent Biologics's current Interest Coverage is 46.21, which is 201% above median its own 10-year median of 15.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innovent Biologics stock overvalued right now?
Based on GuruFocus' analysis, Innovent Biologics (HKSE:01801) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$100.93, compared to a current price of HK$88.95 — trading 11.9% below its estimated fair value. The current Interest Coverage is 46.21, which is 201% above median its 10-year median of 15.36 and 55.6% below the Biotechnology industry median of 104.03. Innovent Biologics' overall GF Score™ is 84/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Innovent Biologics (HKSE:01801), the current Interest Coverage is 46.21 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Innovent Biologics (HKSE:01801) Overvalued in 2026?
Based on GuruFocus' analysis, Innovent Biologics stock appears to be undervalued.
The current stock price of HK$88.95 is trading 11.9% below its estimated GF Value™ of HK$100.93.
GuruFocus considers Innovent Biologics to be Modestly Undervalued.
Key valuation signals for HKSE:01801:
Interest Coverage: 46.21 (201% above median its 10-year median of 15.36)
GF Value™: HK$100.93 vs. price of HK$88.95 (11.9% below fair value)
Industry Position: 55.6% below the Biotechnology median (#240 of 376)
No single metric tells the full story. See the HKSE:01801 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Innovent Biologics is one of the leading biotechnology companies in China. Listed on the Hong Kong stock exchange in 2018, Innovent has 12 commercialized oncology products and four commercialized nononcology products as of January 2026, and 34 drugs in its research and development pipeline. Its core assets are Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists (NRDL) for the first-line treatment of five major cancers, and mazdutide, a GLP-1/glucagon dual agonist drug for weight loss, fat breakdown, and Type 2 diabetes. Mazdutide is the first domestic GLP-1 drug produced and competes with Eli Lilly and Novo Nordisk in China. Tyvyt's main competition includes drugs from Junshi, Jiangsu Hengrui, BeOne, Merck, and Bristol Myers.
84GF Score
Get the complete analysis for HKSE:01801
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01801 has been successfully added to your 
